NCT00305526

REBEAT Resynchronisation and Beta-Blocker European Trial

Resynchronisation and Beta-Blocker European Trial

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 354 (estimated)
• Sponsor: Guidant Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This protocol will evaluate the effect of cardiac resynchronization therapy (CRT) combined with beta-blocker therapy in patients with symptomatic heart failure in whom beta-blocker therapy was either not tolerated or could not be up titrated to optimal doses before CRT. Cardiac resynchronization therapy will be combined with automatic implantable cardioverter defibrillator (AICD, CRT-D) as it has been shown to be associated with an improvement in prognosis in the patients with left ventricular systolic dysfunction and heart failure.

Detailed description

The purpose of this investigation is to evaluate the effect of CRT combined with beta-blocker therapy in patients with symptomatic heart failure in whom beta-blocker therapy was either not tolerated or could not be up-titrated to optimal doses before CRT.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DEVICE	Contak Renewal (CRT-D)

Timeline

• Start date: 2006-04-01
• Completion: 2007-07-01
• First posted: 2006-03-22
• Last updated: 2007-08-09

Locations

3 sites across 2 countries: Italy, Switzerland